In cohort 2, high PODXL expression was an independent prognostic factor in patients with tumours displaying low but not high EGFR expression (unadjusted HR 2.02; 95 % CI 1.02–4.02) and adjusted HR 2.59; 95 % CI 1.26–5.31). This evidence concerns the gene PODXL and neoplasm.